- Home
- »
- Medical Devices
- »
-
Biomarker Discovery Outsourcing Services Market Report 2033GVR Report cover
Biomarker Discovery Outsourcing Services Market (2026 - 2033)
Size, Share & Trends Analysis Report By Biomarker Type (Predictive, Prognostic, Safety, Surrogate), By Therapeutic Area (Oncology, Neurology, Cardiology), By Discovery Phase, By End-use, By Region, And Segment Forecasts
Market Size, 2025
$17.0BMarket Estimate, 2026
$19.9BMarket Forecast, 2033
$76.3BCAGR, 2026–2033
21.1%Biomarker Discovery Outsourcing Services Market Summary
The global biomarker discovery outsourcing services market size was valued at USD 17.0 billion in 2025 and is projected to grow from USD 19.9 billion in 2026 to USD 76.3 billion by 2033, at a CAGR of 21.1% from 2026 to 2033. North America dominated the market, accounting for the largest share of 43.8% in 2025. The industry is anticipated to grow owing to the increasing adoption of precision medicine, rising pharmaceutical and biotechnology research and development expenditure, growing outsourcing of biomarker discovery activities to specialized service providers, expanding application of biomarkers in oncology and other chronic diseases, and continuous advancements in genomics, proteomics, metabolomics, and multi-omics technologies.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By biomarker type: The surrogate endpoints segment led the market with the largest revenue share of 54.5% in 2025.
- By therapeutic area: The oncology segment led the market with the largest revenue share of 34.7% in 2025.
- By discovery phase: The biomarker identification segment led the market with the largest revenue share of 28.6% in 2025.
- By end-use: The biotechnology companies segment led the market with the largest revenue share of 42.5% in 2025.
Regional Highlights
- Largest market: North America (43.8% share in 2025)
- Fastest growing market: Asia Pacific (Highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- 2025 Market Size: USD 17.0 Billion
- 2026 Market Size: USD 19.9 Billion
- 2033 Projected Market Size: USD 76.3 Billion
- CAGR (2026-2033): 21.1%
Prism AI by Grand View Research Free to tryAsk a question about the biomarker discovery outsourcing services market✓Every figure cited from GVR research Prefer the report? Download free sample →
The industry is anticipated to grow owing to the increasing adoption of precision medicine, rising pharmaceutical and biotechnology research and development expenditure, growing outsourcing of biomarker discovery activities to specialized service providers, expanding application of biomarkers in oncology and other chronic diseases, and continuous advancements in genomics, proteomics, metabolomics, and multi-omics technologies. The increasing complexity of biomarker identification and validation workflows, combined with the need for advanced analytical platforms and bioinformatics expertise, is encouraging drug developers to collaborate with specialized outsourcing partners that offer integrated discovery, validation, and data analysis capabilities across multiple therapeutic areas.The increasing adoption of precision medicine remains a primary driver of market growth. Biomarkers play a critical role in patient stratification, target identification, treatment selection, and monitoring therapeutic response, making them an essential component of modern drug development. The growing number of targeted therapies and companion diagnostics entering clinical development is increasing the demand for advanced biomarker discovery services. The requirement for genomic sequencing, transcriptomics, proteomics, and bioinformatics analysis has further increased outsourcing among pharmaceutical and biotechnology companies seeking specialized scientific expertise and access to advanced laboratory technologies without expanding internal research infrastructure.
To learn more about this report, Download Free Sample Report The growing outsourcing of biomarker discovery activities is another important factor supporting market expansion. Biomarker discovery requires access to sophisticated analytical instruments, high-quality biological samples, experienced scientific personnel, and advanced computational capabilities, which involve considerable investment and operational complexity. Therefore, pharmaceutical and biotechnology companies are increasingly partnering with contract research organizations and specialized biomarker service providers to improve development efficiency and accelerate clinical programs. This trend is further supported by continuous investments in advanced biomarker platforms. For instance, in July 2026, CellCarta launched its Global Digital Pathology and AI Consortium to integrate digital pathology, artificial intelligence, and spatial biology capabilities for biomarker discovery, patient stratification, and companion diagnostic development, further strengthening its outsourced biomarker discovery service offerings for precision medicine programs.
Market growth is moderated by the high cost of advanced omics technologies, challenges associated with biomarker validation and regulatory acceptance, and concerns related to biological sample quality and data standardization. The increasing adoption of artificial intelligence-driven biomarker discovery platforms, the expansion of multi-omics research, and the rising investment in precision oncology and personalized therapeutics are expected to create substantial opportunities for biomarker discovery outsourcing service providers over the coming years.
Thus, the biomarker discovery outsourcing services market is expected to witness steady growth as pharmaceutical and biotechnology companies continue to expand precision medicine research, increase outsourcing of specialized discovery activities, and invest in advanced biomarker-driven drug development programs. The continued evolution of multi-omics technologies, bioinformatics, and translational research capabilities is expected to further strengthen demand for integrated biomarker discovery outsourcing services.
Market Dynamics
The rising adoption of precision medicine is a major driver of the biomarker discovery outsourcing services market. Precision medicine depends on reliable biomarkers to identify disease mechanisms, stratify patient populations, predict therapeutic response, and monitor treatment outcomes throughout drug development and clinical practice. The growing development of targeted therapies across oncology, immunology, neurology, and rare diseases has increased the need for advanced biomarker discovery and validation services. Pharmaceutical and biotechnology companies are increasingly outsourcing these activities to specialized service providers with expertise in genomics, proteomics, transcriptomics, metabolomics, and bioinformatics. Outsourcing enables access to advanced analytical technologies, specialized scientific expertise, and integrated data analysis capabilities while reducing infrastructure investment and accelerating biomarker-driven drug development programs.
Challenges associated with biomarker validation and clinical translation remain a key restraint for the biomarker discovery outsourcing services market. Although numerous candidate biomarkers are identified during early research, only a limited number demonstrate adequate analytical, clinical, and clinical utility for regulatory acceptance and routine clinical use. Variability in biological samples, differences in analytical platforms, limited reproducibility across studies, and the absence of standardized validation protocols often delay biomarker qualifications. In addition, extensive clinical studies and regulatory evidence are required before biomarkers can be incorporated into drug development programs or companion diagnostics. These factors increase development timelines, research costs, and project uncertainty for both service providers and pharmaceutical companies.
The expanding use of artificial intelligence in biomarker discovery presents a significant opportunity for the biomarker discovery outsourcing services market. Artificial intelligence and machine learning technologies are increasingly being integrated with genomics, proteomics, imaging, and multi-omics datasets to identify novel biomarkers, improve predictive modeling, and accelerate target discovery. The growing volume of biological and clinical data has increased demand for outsourcing partners capable of combining advanced computational analytics with laboratory-based biomarker discovery services. Service providers are investing in artificial intelligence platforms, cloud-based bioinformatics infrastructure, and multi-omics data integration capabilities to strengthen their service portfolios. The continued adoption of artificial intelligence across pharmaceutical research is expected to improve the efficiency of biomarker identification, reduce discovery timelines, and create new growth opportunities for specialized biomarker discovery outsourcing companies.
Market Concentration & Characteristics
The industry growth stage is high, and growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion.
Innovation remains a key competitive factor in the industry, with service providers investing in advanced multi-omics technologies, artificial intelligence-based analytics, next-generation sequencing, spatial biology, and single-cell analysis platforms. The increasing focus on precision medicine, targeted therapies, and companion diagnostics is encouraging the development of integrated biomarker discovery workflows that improve biomarker identification, validation, and translational research. Continuous technological advancements enable outsourcing providers to improve analytical accuracy, accelerate discovery timelines, and deliver comprehensive data insights across diverse therapeutic areas.
To learn more about this report, Download Free Sample Report Mergers and acquisitions continue to influence the industry by expanding scientific expertise, strengthening multi-omics and bioinformatics capabilities, and broadening global laboratory networks. Strategic acquisitions enable service providers to enhance biomarker discovery, translational research, clinical biomarker testing, and data analysis capabilities while increasing access to advanced analytical technologies. These transactions also improve operational scale, diversify service portfolios, and strengthen competitive positioning as pharmaceutical and biotechnology companies increase outsourcing of biomarker research.
Regulatory compliance remains a major factor shaping the industry. Service providers are required to comply with Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Clinical Laboratory Improvement Amendments (CLIA), College of American Pathologists (CAP) accreditation requirements where applicable, data privacy regulations, and quality management standards governing biological sample handling and laboratory operations. Compliance with these requirements improves data quality, analytical reliability, and regulatory acceptance while increasing operational complexity and quality assurance requirements.
Biomarker discovery outsourcing service providers are expanding their service portfolios to deliver integrated solutions across the biomarker development workflow. Many organizations now provide study design, biospecimen management, genomics, proteomics, transcriptomics, metabolomics, bioinformatics, biomarker validation, and statistical analysis through a single platform. Integrated service offerings improve project coordination, reduce operational complexity, and enable pharmaceutical and biotechnology companies to accelerate biomarker-driven drug development and precision medicine research.
Regional expansion continues to strengthen the global presence of biomarker discovery outsourcing service providers. Companies are expanding laboratory infrastructure, bioinformatics capabilities, and scientific operations across North America, Europe, and the Asia Pacific to address increasing demand for biomarker research and precision medicine programs. Geographic expansion improves access to clinical samples, strengthens collaboration with pharmaceutical and biotechnology companies, enhances regional regulatory compliance, and supports efficient execution of global biomarker discovery projects.
Analyst Perspective
The biomarker discovery outsourcing services market is driven by increasing adoption of precision medicine, rising pharmaceutical and biotechnology R&D investments, and growing outsourcing of biomarker research to improve drug development efficiency. The expanding pipeline of targeted therapies, biologics, cell and gene therapies, and companion diagnostics is increasing demand for biomarker identification, validation, profiling, and bioinformatics services. The continued growth in oncology, autoimmune diseases, neurology, and rare disease research, along with expanding translational research programs and strategic collaborations between pharmaceutical companies and contract research organizations, supports market growth.
Impact of U.S. Tariffs on the Global Biomarker Discovery Outsourcing Services Market
The current U.S. tariff environment has increased procurement costs for imported laboratory instruments, sequencing platforms, analytical reagents, laboratory consumables, and specialized electronic components used in biomarker discovery workflows. Service provider’s dependent on globally sourced equipment and research materials may experience higher operating expenses, longer procurement timelines, and increased maintenance costs for advanced analytical systems. These factors have contributed to higher project costs for biomarker discovery programs, particularly those involving genomics, proteomics, multi-omics, and high-throughput sequencing technologies.
Biomarker discovery outsourcing providers are responding by diversifying supplier networks, strengthening regional sourcing strategies, and expanding relationships with domestic manufacturers of laboratory consumables and research equipment. Pharmaceutical and biotechnology companies continue to outsource biomarker discovery activities due to the specialized expertise, advanced analytical capabilities, and computational infrastructure required for precision medicine research. The sustained investment in targeted therapies, companion diagnostics, and multi-omics research is expected to support long-term demand for biomarker discovery outsourcing services, while increasing regional laboratory capacity and localized supply chains are likely to improve operational resilience despite continuing tariff-related cost pressures.
Technological Advancements
Technological innovation continues to reshape the biomarker discovery outsourcing services market by improving the accuracy, efficiency, and scalability of biomarker identification and validation workflows. The integration of advanced sequencing platforms, multi-omics analysis, artificial intelligence-based data interpretation, spatial biology, and single-cell technologies is enabling service providers to deliver comprehensive discovery solutions across the drug development pipeline. These technologies support faster identification of clinically relevant biomarkers, improved patient stratification, and stronger translational research outcomes while managing increasingly complex biological datasets. Pharmaceutical and biotechnology companies are expanding collaborations with specialized outsourcing partners that possess advanced laboratory infrastructure, computational expertise, and integrated analytical capabilities that may not be economically feasible to establish internally. The increasing complexity of precision medicine research, along with the growing use of targeted therapies and companion diagnostics, is driving continued investment in advanced biomarker discovery technologies.
To learn more about this report, Download Free Sample Report Furthermore, improvements in laboratory automation, cloud-based bioinformatics infrastructure, and data integration capabilities are strengthening operational efficiency and supporting higher project throughput. Continued technological progress is expected to expand the scope of outsourced biomarker discovery services, improve research productivity, and strengthen the long-term growth potential of the global biomarker discovery outsourcing services market.
Pricing Model Analysis
To learn more about this report, Download Free Sample Report The industry utilizes multiple pricing models to accommodate varying research requirements across pharmaceutical, biotechnology, and academic organizations. Project-based pricing remains suitable for studies with clearly defined objectives and deliverables, while the full-time equivalent model supports long-term collaborations that require dedicated scientific expertise and continuous project execution. Sample-based pricing is widely implemented for studies with predictable testing volumes, enabling efficient budgeting for large-scale biomarker screening and validation programs. Platform or assay-based pricing allows clients to access specialized analytical technologies based on the scientific complexity of individual projects. The selection of a pricing model is influenced by study design, sample volume, analytical methodologies, engagement duration, data analysis requirements, and regulatory expectations.
Service providers increasingly offer flexible commercial structures that combine multiple pricing approaches to address changing research priorities and project scope. As biomarker discovery programs continue to incorporate advanced multi-omics technologies, artificial intelligence-driven analytics, and precision medicine applications, pricing strategies are expected to remain adaptable while supporting efficient resource utilization and long-term research partnerships across the industry.
Biomarker Type Insights
Based on biomarker type, the surrogate endpoints segment led the market with the largest revenue share of 54.5% in 2025. The segment's dominance is attributed to the increasing use of surrogate endpoints in clinical trials to assess treatment efficacy and accelerate drug development timelines. Pharmaceutical and biotechnology companies are increasingly incorporating validated surrogate biomarkers into oncology, cardiovascular, and metabolic disease studies to support regulatory submissions and clinical decision-making. The growing adoption of precision medicine and biomarker-driven clinical development has further increased demand for outsourced discovery and validation services for surrogate endpoint biomarkers.
The predictive biomarkers segment is projected to register the fastest CAGR during the forecast period. The increasing development of targeted therapies and companion diagnostics is driving demand for predictive biomarkers that identify patients most likely to respond to specific treatments. Growing investments in precision oncology, immunotherapy, and personalized medicine are encouraging pharmaceutical companies to expand biomarker discovery programs through specialized outsourcing providers. Furthermore, advances in genomics, multi-omics, and artificial intelligence-based data analysis are expected to accelerate the identification and validation of predictive biomarkers, supporting rapid segment growth.
Therapeutic Area Insights
Based on therapeutic area, the oncology segment led the market with the largest revenue share of 34.7% in 2025. The segment's dominance is attributed to the increasing use of biomarkers in cancer diagnosis, patient stratification, treatment selection, and therapeutic response monitoring. The growing development of targeted therapies, immunotherapies, and companion diagnostics has substantially increased the demand for biomarker discovery services across oncology drug development. Furthermore, rising investments in precision oncology research and the expanding clinical pipeline of cancer therapeutics continue to support the outsourcing of biomarker discovery and validation activities.
The autoimmune diseases segment is projected to register the fastest CAGR during the forecast period. The increasing prevalence of autoimmune disorders and the development of biologics and precision therapies are driving demand for biomarkers that enable early diagnosis, patient stratification, and assessment of treatment response. Pharmaceutical and biotechnology companies are expanding biomarker research to support the development of targeted therapies for diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Furthermore, advances in multi-omics technologies and immune profiling are expected to accelerate biomarker discovery, supporting the rapid growth of the segment.
Discovery Phase Insights
Based on discovery phase, the biomarker identification segment led the market with the largest revenue share of 28.6% in 2025. The segment's dominance is attributed to the growing number of drug discovery and translational research programs that require the identification of novel biomarkers across oncology, neurology, cardiovascular, and other therapeutic areas. Pharmaceutical and biotechnology companies are increasingly outsourcing biomarker identification to access advanced capabilities in genomics, proteomics, transcriptomics, and bioinformatics. The growing adoption of precision medicine and multi-omics technologies has further strengthened demand for outsourced biomarker identification services.
The biomarker validation segment is projected to register the fastest CAGR during the forecast period. The increasing focus on translating candidate biomarkers into clinically relevant tools is driving demand for robust validation studies that establish analytical performance, clinical relevance, and reproducibility. The growing development of targeted therapies, companion diagnostics, and precision medicine approaches is encouraging pharmaceutical companies to expand biomarker validation activities through specialized outsourcing providers. Furthermore, increasing regulatory expectations for validated biomarkers in clinical research and drug development are expected to support the rapid growth of the segment.
End-use Insights
Based on end use, the biotechnology companies segment led the market with the largest revenue share of 42.5% in 2025. The segment's dominance is attributed to the increasing focus of biotechnology companies on precision medicine, targeted therapies, and biologics, which require extensive biomarker discovery throughout the drug development process. Many biotechnology companies outsource biomarker discovery activities to specialized service providers to access advanced multi-omics technologies, bioinformatics expertise, and high-end analytical platforms while reducing capital investment and accelerating research timelines.
To learn more about this report, Download Free Sample Report The pharmaceutical companies segment is projected to register the fastest CAGR during the forecast period. The increasing integration of biomarkers into clinical development, companion diagnostic programs, and personalized medicine strategies is driving pharmaceutical companies to expand the outsourcing of biomarker discovery services. Growing investments in oncology, autoimmune diseases, and rare disease therapeutics, along with the need for efficient patient stratification and treatment response assessment, are expected to further drive the segment's rapid growth over the forecast period.
Regional Insights
North America biomarker discovery outsourcing services marketled with the largest revenue share of 43.8% in 2025. The market is supported by increasing investments in precision medicine, expanding pharmaceutical and biotechnology research, and the growing adoption of biomarker-driven drug development. Rising demand for targeted therapies, companion diagnostics, and multi-omics research is increasing the outsourcing of biomarker discovery to specialized service providers. The region benefits from advanced research infrastructure, widespread adoption of next-generation sequencing and artificial intelligence-based analytics, and the presence of leading contract research organizations. Continued investment in translational research and clinical development is expected to support market growth over the forecast period.
To learn more about this report, Download Free Sample Report U.S. Biomarker Discovery Outsourcing Services Market Trends
The biomarker discovery outsourcing services market in the U.S. held the largest share in North America in 2025. Market growth is supported by the presence of a large pharmaceutical and biotechnology industry, increasing development of precision therapies, and substantial investment in oncology and rare disease research. The growing adoption of genomics, proteomics, and artificial intelligence-driven biomarker discovery is driving demand for specialized outsourcing partners. In addition, strong research funding, advanced laboratory infrastructure, and increasing collaboration between industry and research institutions are expected to contribute to sustained market expansion.
The Canada biomarker discovery outsourcing services market is growing steadily owing to increasing investments in life sciences research, expanding biotechnology activities, and rising adoption of precision medicine. The growing focus on translational research, genomics, and personalized healthcare is increasing demand for outsourced biomarker discovery services. Furthermore, government support for biomedical innovation and collaboration between academic institutions and biotechnology companies are expected to strengthen market growth during the forecast period.
Europe Biomarker Discovery Outsourcing Services Market Trends
The biomarker discovery outsourcing services market in Europe is experiencing steady growth, supported by a well-established pharmaceutical and biotechnology industry, increasing precision medicine research, and strong adoption of biomarker-guided drug development. Growing investment in oncology, immunology, and neurological research is increasing demand for outsourced biomarker discovery and validation services. The region benefits from advanced research infrastructure, established clinical research networks, and increasing implementation of multi-omics technologies. Continued investment in translational research and companion diagnostics is expected to support market growth over the forecast period.
The Germany biomarker discovery outsourcing services market is witnessing stable growth owing to its advanced pharmaceutical industry, strong biomedical research capabilities, and increasing development of personalized therapies. Rising investments in translational medicine, molecular diagnostics, and biomarker-based clinical research are increasing outsourcing activities. Furthermore, collaboration between biotechnology companies, research organizations, and healthcare institutions is expected to strengthen demand for biomarker discovery services.
The biomarker discovery outsourcing services market in the UK is expected to grow significantly over the forecast period. Growth is supported by a strong biotechnology ecosystem, increasing clinical research activity, and continued investment in genomics and precision medicine. The presence of leading research institutions, pharmaceutical companies, and specialized contract research organizations is increasing demand for outsourced biomarker discovery services. In addition, government initiatives supporting life sciences innovation are expected to contribute to sustained market growth.
Asia Pacific Biomarker Discovery Outsourcing Services Market Trends
The biomarker discovery outsourcing services market inAsia Pacific is expected to register the fastest growth over the forecast period. Market expansion is supported by increasing pharmaceutical and biotechnology research, growing clinical trial activity, expanding contract research services, and rising investments in precision medicine. The increased availability of skilled scientific professionals, improved research infrastructure, and lower operational costs are encouraging global pharmaceutical companies to outsource biomarker discovery activities to the region. Continued investment in genomics and multi-omics research is expected to further support market growth.
The Japan biomarker discovery outsourcing services market is experiencing steady growth due to increasing investment in precision medicine, regenerative medicine, and oncology research. The country's advanced healthcare infrastructure and strong pharmaceutical industry are supporting greater adoption of biomarker-based drug development. Furthermore, increasing use of genomic technologies and translational research is expected to strengthen demand for outsourced biomarker discovery services.
The biomarker discovery outsourcing services market in China is witnessing rapid growth, driven by expanding pharmaceutical and biotechnology industries, rising research and development expenditures, and strong government support for biotechnology innovation. Rising investment in genomics, precision medicine, and clinical research is increasing demand for outsourced biomarker discovery services. Furthermore, expanding contract research capabilities and modern laboratory infrastructure are expected to support continued market expansion.
The India biomarker discovery outsourcing services market is expected to grow at a significant pace owing to the expanding contract research industry, increasing pharmaceutical and biotechnology research activities, and the availability of a highly skilled scientific workforce. Growing investment in genomics, bioinformatics, and clinical research, along with competitive operating costs, is encouraging global companies to outsource biomarker discovery activities to India.
Latin America Biomarker Discovery Outsourcing Services Market Trends
The biomarker discovery outsourcing services market inLatin America is experiencing gradual growth, supported by expanding clinical research activities, increasing investment in biotechnology, and growing adoption of precision medicine. Rising collaboration between pharmaceutical companies and regional research institutions is increasing demand for biomarker discovery services. Continued improvement in research capabilities and healthcare infrastructure is expected to support market growth across the region.
The Brazil biomarker discovery outsourcing services market accounted for the largest share in Latin America in 2025.Market growth is supported by increasing pharmaceutical research, expanding clinical trial activity, and rising investment in biotechnology and molecular diagnostics. Furthermore, growing collaboration between academic institutions, healthcare organizations, and pharmaceutical companies is expected to strengthen demand for outsourced biomarker discovery services.
Middle East & Africa Biomarker Discovery Outsourcing Services Market Trends
The biomarker discovery outsourcing services market in theMiddle East & Africa is experiencing gradual growth owing to increasing investment in healthcare research, expanding biotechnology capabilities, and growing interest in precision medicine. Rising government initiatives to strengthen biomedical research infrastructure and increasing collaboration with international pharmaceutical companies are contributing to market development. The growing adoption of molecular diagnostics and genomics research is expected to support future demand for biomarker discovery outsourcing services.
The UAE biomarker discovery outsourcing services market is expected to grow rapidly, driven by increasing investment in life sciences, precision medicine, and genomic research, as well as the development of advanced healthcare and research infrastructure. Furthermore, government initiatives promoting biotechnology innovation and international research collaborations are expected to increase demand for outsourced biomarker discovery services in the country.
Key Biomarker Discovery Outsourcing Services Company Insights
The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in April 2025, Labcorp launched Labcorp Plasma Detect for molecular residual disease (MRD) assessment and expanded the availability of PGDx elio plasma focus Dx, an FDA-authorized liquid biopsy assay for comprehensive genomic profiling. The launch strengthened the company's precision oncology and biomarker testing portfolio, supporting biomarker-driven drug development and personalized treatment strategies.
Key Biomarker Discovery Outsourcing Services Companies:
The following key companies have been profiled for this study on the biomarker discovery outsourcing services market
-
LabCorp
-
Charles River Laboratories International, Inc.
-
Eurofins Scientific
-
Celerion
-
ICON plc
-
Parexel International (MA) Corporation
-
Proteome Sciences
-
GHO Capital
-
Thermo Fisher Scientific Inc.
-
Evotec
Competitive Benchmarking
Operating Strategies
Competitive Edge
Weakness
Established Players: Labcorp, Eurofins Scientific
- Established players focus on expanding integrated biomarker discovery capabilities across genomics, proteomics, transcriptomics, metabolomics, bioinformatics, and biomarker validation. These companies invest in advanced sequencing platforms, artificial intelligence-based analytics, digital pathology, multi-omics technologies, and global laboratory infrastructure while offering end-to-end services from biomarker discovery through clinical validation and translational research.
- Established players benefit from extensive global laboratory networks, broad technology portfolios, advanced analytical infrastructure, and strong relationships with pharmaceutical and biotechnology companies. Their ability to provide integrated biomarker discovery, bioinformatics, clinical biomarker testing, and regulatory support across multiple therapeutic areas enables them to manage large, multi-site research programs while maintaining high-quality, standardized laboratory operations.
- Established players face challenges including high investment requirements for advanced laboratory technologies, rising operational costs, and the ongoing need to upgrade sequencing, bioinformatics, and data management platforms. Large organizational structures may also reduce operational flexibility and extend project initiation timelines compared with specialized niche providers.
Emerging Player: Celerion
- Emerging players primarily focus on specialized biomarker discovery services such as proteomics, metabolomics, translational research, single-cell analysis, spatial biology, and precision medicine applications. Many strengthen their market presence through strategic collaborations, technology partnerships, specialized service launches, and investments in advanced analytical platforms that address specific therapeutic and research requirements.
- Emerging players gain competitive advantages through specialized scientific expertise, flexible project execution, customized service offerings, and rapid adoption of emerging technologies. Their focused capabilities enable efficient execution of complex biomarker discovery studies, particularly for biotechnology companies and early-stage drug development programs requiring tailored analytical solutions.
- Emerging players often face limitations in global laboratory presence, financial resources, and large-scale project execution. Limited brand recognition, smaller client portfolios, and restricted access to comprehensive multi-omics infrastructure may affect their ability to compete for large international outsourcing programs with established global service providers.
Recent Developments
-
In July 2026, CellCarta launched its Global Digital Pathology and AI Consortium, bringing together leading artificial intelligence, digital pathology, spatial biology, and precision diagnostics companies to accelerate biomarker discovery, patient stratification, clinical trial execution, and companion diagnostic development across multiple therapeutic areas. The initiative expands CellCarta's biomarker discovery and translational research capabilities for biopharmaceutical customers.
-
In August 2025, Aptamer Group launched a novel biomarker discovery service integrating its proprietary Optimer technology with advanced proteomic analysis to enable high-throughput identification and validation of disease biomarkers. The platform is designed to accelerate biomarker discovery for pharmaceutical, biotechnology, and diagnostic developers by delivering validated biomarkers together with affinity ligands for downstream therapeutic and diagnostic applications.
Biomarker Discovery Outsourcing Services Market Report Scope
Report Attribute
Details
Market size value in 2025
USD 17.0 billion
Market size value in 2026
USD 19.9 billion
Revenue forecast in 2033
USD 76.3 billion
Growth rate
CAGR of 21.1% from 2026 to 2033
Actual Data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Biomarker type, therapeutic area, discovery phase, end-use, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait; Oman; Qatar
Key companies profiled
Laboratory Corporation of America Holdings (LabCorp); Charles River Laboratories; Eurofins Scientific; Celerion; ICON plc; Parexel International (MA) Corporation; Proteome Sciences; GHO Capital; Thermo Fisher Scientific Inc.; Evotec.
Customization scope
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Biomarker Discovery Outsourcing Services Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biomarker discovery outsourcing services market report based on biomarker type, therapeutic area, discovery phase, end-use, and region:
-
Biomarker Type Outlook (Revenue, USD Billion, 2021 - 2033)
-
Predictive Biomarkers
-
Prognostic Biomarkers
-
Safety Biomarkers
-
Surrogate Endpoints
-
-
Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)
-
Oncology
-
Neurology
-
Cardiology
-
Autoimmune Diseases
-
Other Therapeutic Area
-
-
Discovery Phase Outlook (Revenue, USD Billion, 2021 - 2033)
-
Biomarker Identification
-
Biomarker Validation
-
Biomarker Profiling
-
Biomarker Panel Development
-
Biomarker Selection
-
-
End-use Outlook (Revenue, USD Billion, 2021 - 2033)
-
Pharmaceutical Companies
-
Biotechnology Companies
-
Other End Use
-
-
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
UAE
-
Saudi Arabia
-
Kuwait
-
Qatar
-
Oman
-
-
Research Methodology
The biomarker discovery outsourcing services market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each biomarker discovery outsourcing services segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Biomarker Type
Revenue Capture Definition
Predictive Biomarkers
The segment captures revenue generated from outsourced biomarker discovery services focused on identifying biomarkers that predict patient response to specific therapies. Services include biomarker identification, assay development, multi-omics analysis, bioinformatics, and validation supporting precision medicine and companion diagnostic development.
Prognostic Biomarkers
The segment captures revenue generated from outsourced biomarker discovery services for biomarkers used to predict disease progression, recurrence, or clinical outcomes, irrespective of treatment. Revenue includes biomarker discovery, profiling, validation, and data analysis services across multiple therapeutic areas.
Safety Biomarkers
The segment captures revenue generated from outsourced biomarker discovery services for identifying biomarkers associated with drug toxicity, adverse effects, and treatment safety. Services include toxicogenomics, proteomics, metabolomics, biomarker validation, and translational research supporting preclinical and clinical drug development.
Surrogate Endpoints
The segment captures revenue generated from outsourced biomarker discovery services focused on identifying and validating surrogate endpoint biomarkers used as substitutes for clinical endpoints in drug development and clinical trials. Services include biomarker identification, validation, analytical testing, and statistical evaluation.
Segment - Therapeutic Area
Revenue Capture Definition
Oncology
The segment captures revenue generated from outsourced biomarker discovery services supporting oncology drug development. Services include biomarker identification, tumor profiling, genomic and proteomic analysis, companion diagnostic development, biomarker validation, and bioinformatics for cancer research and precision oncology.
Neurology
The segment captures revenue generated from outsourced biomarker discovery services supporting neurological disease research. Services include biomarker identification, multi-omics analysis, validation, and translational research for neurodegenerative disorders, neuroinflammatory diseases, and other neurological conditions.
Cardiology
The segment captures revenue generated from outsourced biomarker discovery services supporting cardiovascular drug development and clinical research. Services include biomarker identification, proteomic and metabolomic analysis, validation, and data interpretation for cardiovascular diseases.
Autoimmune Diseases
The segment captures revenue generated from outsourced biomarker discovery services supporting research and development of therapies for autoimmune disorders. Services include immune profiling, biomarker identification, validation, genomics, and multi-omics analysis for precision medicine applications.
Other Therapeutic Area
The segment captures revenue generated from outsourced biomarker discovery services supporting therapeutic areas including infectious diseases, metabolic disorders, respiratory diseases, rare diseases, and other clinical indications requiring biomarker discovery and validation.
Segment - Discovery Phase
Revenue Capture Definition
Biomarker Identification
The segment captures revenue generated from outsourced services focused on the discovery of novel biomarkers using genomics, proteomics, transcriptomics, metabolomics, single-cell analysis, spatial biology, and bioinformatics technologies during early-stage research.
Biomarker Validation
The segment captures revenue generated from outsourced services that evaluate the analytical performance, reproducibility, and clinical relevance of identified biomarkers. Services include assay validation, statistical analysis, clinical sample testing, and regulatory support.
Biomarker Profiling
The segment captures revenue generated from outsourced biomarker profiling services involving comprehensive molecular characterization of biological samples using multi-omics technologies to identify disease associated biomarker signatures and therapeutic targets.
Biomarker Panel Development
The segment captures revenue generated from outsourced services for developing multiplex biomarker panels that combine multiple biomarkers for disease diagnosis, patient stratification, prognosis, and treatment response assessment.
Biomarker Selection
The segment captures revenue generated from outsourced services for selecting the most clinically relevant biomarkers based on analytical performance, biological significance, and intended application in drug development, clinical trials, or companion diagnostics.
Segment - End Use
Revenue Capture Definition
Pharmaceutical Companies
The segment captures revenue generated from biomarker discovery outsourcing services provided to pharmaceutical companies for drug discovery, clinical development, precision medicine, companion diagnostics, and regulatory research programs.
Biotechnology Companies
The segment captures revenue generated from biomarker discovery outsourcing services provided to biotechnology companies developing biologics, targeted therapies, cell and gene therapies, and personalized medicines requiring biomarker discovery and validation.
Other End Use
The segment captures revenue generated from biomarker discovery outsourcing services provided to academic research institutes, government research organizations, diagnostic companies, hospitals, and other organizations engaged in biomarker research and translational medicine.
Estimation Model
Bottom-Up Revenue Model
Clinical Pipeline Based Demand Model
Sample Volume Based Estimation Model
Outsourcing Penetration Model
- Market size is estimated by identifying major and emerging biomarker discovery outsourcing service providers offering biomarker identification, validation, profiling, biomarker panel development, bioinformatics, and translational research services.
- Revenue attributable to biomarker discovery outsourcing services is derived from annual reports, investor presentations, company disclosures, financial filings, service portfolios, and management commentary.
- Company-level revenues are aggregated and validated by assessing laboratory infrastructure, technology capabilities, therapeutic expertise, customer base, geographic presence, and industry benchmarks to estimate the overall market value.
- Market value is estimated by evaluating the number of drug candidates progressing through discovery, preclinical, Phase I, Phase II, Phase III, and commercial development that incorporate biomarker-driven research.
- Average outsourcing expenditure is assigned to biomarker discovery activities, including biomarker identification, validation, multi-omics analysis, bioinformatics, and translational research across each stage of development.
- The number of drug programs is multiplied by the estimated biomarker outsourcing expenditure and aggregated across oncology, neurology, cardiology, autoimmune diseases, and other therapeutic areas to estimate total demand market.
- Market size is estimated using the annual volume of biological samples processed for outsourced biomarker discovery studies across pharmaceutical, biotechnology, and academic research organizations.
- Key parameters include average samples processed per project, analytical technologies utilized, project complexity, assay mix, laboratory throughput, utilization rates, and average pricing per sample or analytical workflow.
- Total sample processing volume is converted into annual service revenue and validated against laboratory capacity, reported project volumes, technology adoption, and industry utilization benchmarks.
- Market value is estimated by the proportion of pharmaceutical and biotechnology companies outsourcing biomarker discovery activities rather than conducting research through internal laboratories.
- Outsourcing penetration rates are determined through primary interviews, industry publications, company disclosures, strategic collaborations, and contract research trends across precision medicine and translational research.
- The addressable market is calculated by applying outsourcing penetration rates to total spending on biomarker discovery, biomarker validation, bioinformatics, multi-omics analysis, and related research activities, thereby estimating the overall biomarker discovery outsourcing services market opportunity.
Summary
This estimation framework enhances market visibility by integrating revenues from biomarker discovery outsourcing service providers, pharmaceutical and biotechnology research expenditure, biomarker-driven drug development pipelines, outsourced biomarker research activity, laboratory capacity, and sample processing volumes, resulting in a comprehensive understanding of the biomarker discovery outsourcing services market. The triangulated methodology improves forecast reliability by capturing evolving outsourcing trends and the increasing demand for biomarker identification, validation, profiling, multi-omics analysis, bioinformatics, and translational research services. This approach enables precise identification of growth opportunities, competitive positioning, technology investment priorities, and expansion potential while reducing reliance on any single estimation methodology.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Industry Outlook, Value Chain, and Business Model Assessment
Conducted a comprehensive evaluation of the biomarker discovery outsourcing services ecosystem, covering biospecimen providers, academic and research institutes, sequencing and analytical technology providers, bioinformatics companies, contract research organizations (CROs), biomarker discovery service providers, diagnostic developers, pharmaceutical and biotechnology companies, and regulatory stakeholders. Assessed prevailing business models, outsourcing trends, revenue streams, pricing structures, service delivery models, technology adoption, and value creation opportunities across biomarker identification, validation, profiling, bioinformatics, and translational research.
Provides a comprehensive understanding of the industry ecosystem, outsourcing landscape, revenue opportunities, and value chain dynamics, enabling stakeholders to identify growth areas, optimize partnership strategies, and support investment decisions across the biomarker discovery outsourcing services market.
Competitive Benchmarking and Technology Capability Analysis
Performed detailed benchmarking of leading biomarker discovery outsourcing service providers based on multiomics capabilities, genomics and proteomics expertise, next generation sequencing platforms, spatial biology, single cell analysis, bioinformatics capabilities, laboratory infrastructure, therapeutic expertise, regulatory compliance, geographic presence, strategic collaborations, and integrated biomarker discovery and validation services. Included comparative positioning of global CROs, specialized biomarker service providers, and precision medicine companies.
Enables identification of competitive differentiation, technology leadership, partnership opportunities, acquisition targets, and capability gaps, supporting strategic planning and long-term positioning within the biomarker discovery outsourcing services market.
Global Regulatory Landscape and Compliance Assessment
Conducted a comprehensive assessment of regulatory and quality requirements governing biomarker discovery and translational research across North America, Europe, Asia Pacific, and other major markets. The analysis covered Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Clinical Laboratory Improvement Amendments (CLIA), College of American Pathologists (CAP) accreditation, biological sample management, laboratory quality systems, data integrity, and privacy regulations affecting biomarker research. Also evaluated regional regulatory differences and their impact on outsourcing strategies and laboratory operations.
Enables pharmaceutical companies, biotechnology firms, and service providers to understand evolving regulatory expectations, strengthen compliance strategies, minimize operational risks, and support market entry and expansion decisions across global biomarker discovery outsourcing services.
Frequently Asked Questions About This Report
The global biomarker discovery outsourcing services market size was valued at USD 17.0 billion in 2025 and is estimated at USD 19.9 billion in 2026.
The global biomarker discovery outsourcing services market is expected to grow at a CAGR of 21.1% from 2026 to 2033, reaching USD 76.3 billion by 2033.
North America dominated with a 43.8% revenue share in 2025.
The surrogate endpoints segment led with a 54.5% revenue share in 2025, while predictive biomarkers segment is fastest growing biomarker type.
Key factors include increasing adoption of precision medicine, rising pharmaceutical and biotechnology research and development expenditure, growing outsourcing of biomarker discovery activities to specialized service providers, expanding application of biomarkers in oncology and other chronic diseases, and continuous advancements in genomics, proteomics, metabolomics, and multi-omics technologies.
The biomarker identification segment led with a 28.6% revenue share in 2025, while biomarker validation segment is fastest growing discovery phase.
The oncology segment held the largest revenue share of 34.7% in 2025, while autoimmune diseases segment is fastest growing therapeutic area.
Key players include Laboratory Corporation of America Holdings; Charles River Laboratories; Eurofins Scientific; Celerion; ICON plc; Parexel International (MA) Corporation; Proteome Sciences; GHO Capital; Thermo Fisher Scientific Inc.; Evotec, among others.
Asia Pacific is the fastest-growing region over the forecast period.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
